ADPGK and neoplasm: After 9 days of MC38 tumor inoculation, tumor‐bearing mice were administered with PEG(15) NPs via intratumoral, subcutaneous (s.c.), or intravenous (i.v.)routes, which resulted in elicitation of 14 ± 3.1, 6.9 ± 5.6, and 5.8 ± 7.4% Adpgk‐specific CD8+ T cell response, respectively, on day 16 (Figure 6C).